Online citations, reference lists, and bibliographies.
← Back to Search

Non-pegylated Liposomal Doxorubicin And Docetaxel In Metastatic Breast Cancer: Final Results Of A Phase II Trial

P. Schmid, J. Krocker, R. Kreienberg, P. Klare, K. Kittel, H. Sommer, G. Heinrich, T. Steck, W. Lichtenegger, D. Elling, S. Kuemmel
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundNon-pegylated liposomal doxorubicin (NPLD) has demonstrated equivalent antitumor activity to conventional doxorubicin and a significantly lower risk of cardiotoxicity when given as single agent or in combination with cyclophosphamide, but there is limited experience with the combination of NPLD and taxanes. This phase II study was performed to evaluate the efficacy and safety of the NPLD and docetaxel in patients with metastatic breast cancer.Patients and methodsA total of 51 patients were treated with NPLD (60 mg/m2) and docetaxel (75 mg/m2) in 3-weeks intervals for up to eight cycles.ResultsThe overall response rate was 50% and 78% of patients derived a clinical benefit. Median time to progression and overall survival were 10.0 months (95% CI, 6.9–13.1 months) and 25 months (95% CI, 22.1–29.8 months), respectively. Median duration of response was 12.0 months (95% CI 7.1–16.9). The treatment was generally well tolerated and associated with toxicities that were consistent with the known side-effects of the individual agents and of anthracycline/taxane combinations. There were no symptomatic cardiac averse events and mild asymptomatic LVEF changes were reported in five patients.ConclusionsThe combination of NPLD and docetaxel is well tolerated and has high antitumour activity in MBC patients.
This paper references
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
TLC D-99 Study Group (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as Wrst-line therapy of metastatic breast carcinoma
L Harris (2002)
10.7326/0003-4819-126-10-199705150-00020
Anthracycline-induced cardiotoxicity.
K. Shan (1996)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
10.1200/JCO.2005.06.236
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
M. Bontenbal (2005)
10.1200/JCO.1999.17.5.1413
Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy
J. M. Nabholtz (1999)
10.1093/ANNONC/MDH393
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
S. Chan (2004)
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as Wrst-line chemotherapy in metastatic breast cancer: EORTC 10961
L Biganzoli (2002)
10.1200/JCO.1999.17.8.2341
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)
10.1200/JCO.2001.19.6.1707
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
J. Jassem (2001)
10.1200/JCO.2002.11.005
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
L. Biganzoli (2002)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1200/JCO.2003.08.013
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
10.1200/JCO.2007.10.8399
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
M. Piccart-Gebhart (2008)
Pegylated Liposomal Doxorubicin: Scientific Rationale and Preclinical Pharmacology
F. J. Martin (1997)
10.1200/JCO.2002.09.002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
The Biodistribution and Pharmacokinetics of Stealth Liposomes in Patients with Solid Tumors
S. Stewart (1997)
10.1200/JCO.2000.18.4.724
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
R. Paridaens (2000)
10.3109/14733400500089500
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
A. A. García (2005)
Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
A. Cabanes (1998)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Pegylated liposomal dixirubicin: ScientiWc rationale and prelinical pharmacology
FJ Martin (1997)
10.1200/JCO.2003.04.040
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
10.1038/sj.bjc.6602179
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
J. Bonneterre (2004)



This paper is referenced by
10.1179/joc.2011.23.1.49
Successful Multimodal Treatment of a Breast Cancer Patient with a Recurrence Invading the Chest Wall
G. Corrado (2011)
10.1016/j.jpba.2009.06.028
Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence.
H. S. Kim (2010)
10.2147/BCTT.S6127
New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.
I. Macpherson (2009)
10.1016/j.breast.2010.05.008
Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
D. Bernardi (2010)
10.1007/s12609-012-0099-z
The Role of Liposomal Anthracyclines in Metastatic Breast Cancer
A. Gennari (2013)
10.1371/journal.pone.0133569
Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials
Meiyuan Xing (2015)
First-Line Chemotherapy with Anthracycline and Taxane Combination in Metastatic Breast Cancer. Detection of bone metastases with TRACP 5b
Jaana Korpela (2011)
Avaliação do efeito citotóxico de piranonaftoquinonas inibidoras de DNA topoisomerases sobre células de leucemia
M. A. Oliveira (2015)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
10.2147/bctt
Breast Cancer: Targets and Therapy
I. Macpherson (2009)
10.1016/j.ejca.2011.08.004
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
E. Curtit (2011)
10.1002/ADTP.202000159
Clinical Translation of Self‐Assembled Cancer Nanomedicines
P. Mi (2020)
10.1161/JAHA.117.007724
Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review
A. Porta-Sánchez (2017)
Semantic Scholar Logo Some data provided by SemanticScholar